The centrality dependence of strange ( K S 0 , Λ + Λ ¯ ) and multistrange ( Ξ − + Ξ ¯ + , Ω − + Ω ¯ + ) hadron production is measured by ALICE in the Large Hadron Collider (LHC) lead-lead (Pb-Pb) collisions at a center-of-mass energy per nucleon pair s N N = 5.02 TeV, using the full dataset collected during the LHC Run 2 campaign in the years 2015 and 2018. This is the largest heavy-ion dataset analyzed to date at the LHC, and it allows for the extraction of transverse momentum ( p T ) spectra and p T -integrated yields with unprecedented precision, over a broad range of charged particle multiplicity densities ( 〈 d N ch / d η 〉 | η | < 0.5 ), probing regions where smaller collision system ( and p -Pb) results are also available. The p T spectra evolve with centrality, featuring higher 〈 p T 〉 in central events for all particles. The Λ / K S 0 ratio exhibits the distinctive baryon-to-meson enhancement in the intermediate p T region, with a maximum which is shifted to larger p T for more central collisions. The hadron-to-pion yield ratios are presented as a function of 〈 d N ch / d η 〉 | η | < 0.5 and compared to results from different collision systems and energies. A smooth connection from to Pb-Pb is observed, thus demonstrating that collision system or energy do not play a role in the multiplicity evolution of this observable. The previously reported enhancement of strangeness production in the multiplicity range probed in and p -Pb collisions saturates in the multiplicity range of Pb-Pb data. These results constitute a key test bench for theoretical models and a first comparison to the EPOS 4 generator is presented.
Background: Zeste White 10 (ZW10) is a key component of the spindle assembly checkpoint (SAC) that maintains chromosomal stability during mitosis. Dysregulation of ZW10 can cause chromosomal instability and aneuploidy-hallmarks of many cancers, including breast cancer, particularly triple-negative breast cancer (TNBC). However, its prognostic and therapeutic relevance in breast cancer remains unclear. Objectives: This study aimed to systematically investigate the expression pattern, prognostic significance, mutational profile, and immune associations of ZW10 in breast cancer using integrated omics data. Design: A computational, cross-cohort bioinformatics analysis combining transcriptomic, proteomic, mutational, and clinical data from publicly available databases. Methods: The ZW10 expression levels were assessed across normal and cancerous tissues using The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), and the Human Protein Atlas data sets. Immune infiltration correlations were analyzed using TIMER2.0, Gene Set Cancer Analysis (GSCA), and TNMplot. Survival analyses were performed using Kaplan-Meier Plotter and TCGA clinical data sets. Protein-protein interaction (PPI) and functional enrichment analyses were conducted using STRING and EnrichR, and mutation data were retrieved from COSMIC and cBioPortal. Results: The ZW10 expression was markedly upregulated across multiple cancers, with the highest expression in TNBC. Elevated ZW10 levels correlated with immune cell infiltration and adverse overall survival, while lower ZW10 expression predicted improved relapse-free survival. Protein-protein interaction and enrichment analyses revealed ZW10's close interaction with key mitotic regulators and its involvement in spindle checkpoint and vesicular trafficking pathways. Mutation analysis identified predominant A > G and A > T substitutions and frequent gene amplifications across malignancies. Conclusion: The ZW10 acts as a potential prognostic biomarker and therapeutic target in breast cancer, particularly TNBC, through its dual roles in mitotic regulation and immune modulation. Further experimental validation is warranted to confirm its mechanistic role and therapeutic potential.
The coronavirus disease 2019 (COVID-19) pandemic has been associated with a wide range of neurological complications, among which persistent cognitive impairment and memory deficits are increasingly recognized as key symptoms of the post-acute sequelae of SARS-CoV-2 infection (PASC or long COVID). Although clinical and epidemiological studies have documented these symptoms across diverse patient populations, the underlying neurobiological mechanisms remain incompletely understood. Growing evidence from human studies, neuropathological analyses, and experimental models indicates that neuroimmune and inflammatory processes plays a central role in COVID-19-associated cognitive dysfunction. As the brain’s resident immune cells, microglia are vital for synaptic health, neuroplasticity, and memory, yet these processes may be compromised after SARS-CoV-2 infection. Systemic inflammation, blood–brain barrier (BBB) disruption, endothelial injury, and cytokine signaling can induce sustained microglial activation and priming, leading to inflammasome activation, complement-mediated synaptic remodeling, oxidative stress, and impaired hippocampal neurogenesis. These processes collectively disrupt neural circuits involved in learning and memory and may underlie the persistent “brain fog” reported by COVID-19 survivors. This review synthesizes clinical, biomarker, neuroimaging, and mechanistic evidence linking SARS-CoV-2 infection to microglia-mediated neuroinflammation and memory impairment. In contrast to prior reviews that broadly describe neuroinflammation in COVID-19, we integrate multidimensional evidence into a microglia-centric immunovascular framework that highlights converging pathogenic pathways underlying cognitive symptoms. We further discuss emerging biomarkers of glial activation and evaluate current and prospective therapeutic strategies targeting microglial and neuroimmune pathways. Understanding the role of microglial dysregulation in post-COVID cognitive impairment may facilitate the development of targeted interventions to mitigate long-term neurological consequences of COVID-19.
Abstract Fine particulate matter (PM₂.₅) poses significant public and environmental health risks in urban areas. Chicago’s dense industry and traffic create variable air quality, yet monitoring is unevenly distributed, resulting in undersampling of air quality data in some city areas. This study applied a hybrid approach using GIS-based kernel density mapping, interpolation modeling (IDW, Spline, Kriging) of USEPA monitoring data, multi-scale temporal trend analyses (hourly to annual), and ESDA. Accordingly, the density surface showed that monitors are concentrated in the affluent north, northwest, and southwest sides of Chicago (up to ~ 0.07 stations per sq mile), while the south and southeast regions, with predominantly minority communities, have virtually no coverage. Overall, citywide coverage is minimal (~ 4–5 monitors total; ~0.02 per sq mile; ≈1 per 600,000 residents). Temporal analyses showed that the city’s mean annual PM₂.₅ (~ 10.8 µg/m³) exceeds USEPA/WHO standards (9 µg/m³), with summer means (~ 17.1 µg/m³) significantly higher than other seasons. Diurnally, a clear pattern was observed, with PM₂.₅ concentrations peaking overnight (00:00–03:00) and during the morning rush hours, and dipping during midday to late afternoon. Spatial distribution of PM₂.₅ identified hotspots near O’Hare Airport, the downtown Loop area, and south-side neighborhoods, contrasting with lower concentrations on the north side, revealing Chicago’s socioeconomic divides and resulting environmental inequities. The findings underscore the need for expanded monitoring and targeted interventions in under-monitored, high-pollution communities to advance equitable community health.